Search
Chenodeoxycholic acid
go.drugbank.com/drugs/DB06777ApprovedInvestigationalIt works by dissolving the cholesterol that makes gallstones and inhibiting production of cholesterol in the liver and absorption in the intestines, which helps to decrease the formation of gallstones.
Procaterol
go.drugbank.com/drugs/DB01366ApprovedWithdrawnIt is a potent bronchodilator that may be administered orally or by aerosol inhalation.
Tremelimumab
go.drugbank.com/drugs/DB11771ApprovedInvestigational[A253717] By binding to CTLA-4, tremelimumab enhances T cell-mediated killing of tumours and reduces tumour growth. … [A253712] Tremelimumab was first approved by the FDA in October 2022 to be used in combination with [durvalumab] to treat hepatocellular carcinoma.
Sulconazole
go.drugbank.com/drugs/DB06820ApprovedSulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic derma...
Apremilast
go.drugbank.com/drugs/DB05676ApprovedInvestigational[A181244,L7495] Initially approved in 2014, it is marketed by Celgene.
Anethole trithione
go.drugbank.com/drugs/DB13853Approvedappears to have a broad range of unique functions, from increasing salivary secretion to help treat xerostomia [A27165, A32618, A32620, A32621], to demonstrating an ability to inhibit carcinogenesis by
Sodium iodide
go.drugbank.com/drugs/DB11119ApprovedInvestigationalSodium iodide is a source of iodine and can be administered as a supplement for total parenteral nutrition [L2065] but is more commonly used in veterinary medicine.
Mixtures: FERTOMCIDINA U, FERTOMCIDINA UBesilesomab
go.drugbank.com/drugs/DB13979ApprovedUtilised only as a diagnostic agent, besilesomab is currently approved by the EMEA for marketing and use in various European countries like Italy, France, Germany, Spain, Portugal, Norway, Sweden, the
Ad5-nCoV
go.drugbank.com/drugs/DB15655Investigational[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906 … The study will evaluate antibody response in healthy patients between the ages of 18 and 60 who will receive one of three study doses, with follow-up taking place at weeks 2 and 4 and months 3 and 6 post-vaccination